- Home
- IONS
as 07-25-2025 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Upcoming Earnings Alert:
Get ready for potential market movements as Ionis Pharmaceuticals Inc. IONS prepares to release earnings report on 30 Jul 2025.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.8B | IPO Year: | 1991 |
| Target Price: | $57.13 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $52.34 | Next Earning Date: | 07-30-2025 |
| Revenue: | $717,253,000 | Revenue Growth: | -7.64% |
| Revenue Growth (this year): | 9.08% | Revenue Growth (next year): | 14.72% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hayden Michael R | IONS | Director | May 1 '25 | Buy | $31.86 | 15,000 | $477,900.00 | 50,219 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
GlobeNewswire
a month ago
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Investor's Business Daily
a month ago
Can Biogen Save Even More Kids With This New Drug?
MT Newswires
a month ago
Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies
Business Wire
a month ago
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Investor's Business Daily
a month ago
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
GlobeNewswire
a month ago
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Insider Monkey
a month ago
First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.